MARKET

SCYX

SCYX

Scynexis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.060
+0.180
+9.57%
Closed 16:00 05/27 EDT
OPEN
1.870
PREV CLOSE
1.880
HIGH
2.070
LOW
1.870
VOLUME
157.74K
TURNOVER
205.72K
52 WEEK HIGH
10.25
52 WEEK LOW
1.810
MARKET CAP
67.11M
P/E (TTM)
-1.7032
1D
5D
1M
3M
1Y
5Y
SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, Presi...
GlobeNewswire · 05/20 12:30
--HC Wainwright Adjusts Price Target on SCYNEXIS to $8 From $14, Reiterates Buy Rating
MT Newswires · 05/13 06:40
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 12:35
SCYNEXIS: Q1 Earnings Insights
  SCYNEXIS (NASDAQ:SCYX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 11:25
BRIEF-Scynexis Posts Q1 Sales Of $700,000
reuters.com · 05/12 11:18
SCYNEXIS GAAP EPS of -$0.17, revenue of $0.7M
SCYNEXIS press release (NASDAQ:SCYX): Q1 GAAP EPS of -$0.17. Revenue of $0.7M (-65.0% Y/Y). Cash and cash equivalents totaled approximately $95.2 million on March 31, 2022, compared to $104.5 million
Seekingalpha · 05/12 11:02
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurr...
GlobeNewswire · 05/12 11:00
More
No Data
Learn about the latest financial forecast of SCYX. Analyze the recent business situations of Scynexis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SCYX stock price target is 20.00 with a high estimate of 30.00 and a low estimate of 8.00.
High30.00
Average20.00
Low8.00
Current 2.060
EPS
Actual
Estimate
-0.83-0.60-0.38-0.15
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 72
Institutional Holdings: 23.30M
% Owned: 71.51%
Shares Outstanding: 32.58M
TypeInstitutionsShares
Increased
15
5.36M
New
9
301.49K
Decreased
12
404.26K
Sold Out
6
410.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Guy Macdonald
President/Chief Executive Officer/Director
Marco Taglietti
Chief Financial Officer
Lawrence Hoffman
Vice President
Nkechi Azie
General Counsel
Scott Sukenick
Other
David Angulo
Other
Christine Coyne
Independent Director
Armando Anido
Independent Director
Steven Gilman
Independent Director
Ann Hanham
Independent Director
David Hastings
Independent Director
Philippe Tinmouth
No Data
No Data
About SCYX
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous oral agent for multiple fungal indications in both the community and hospital settings. It has received the acceptance letter from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). The FDA has conditionally approved Brexafemme as the brand name for oral ibrexafungerp for vaginal yeast infections. It is also continuing late-stage clinical development for the prevention of recurrent VVC, as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.